XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Revenue (Tables)
3 Months Ended
Mar. 31, 2024
Revenue  
Schedule of revenue recognized from collaborative arrangements

Three Months Ended March 31, 

(In thousands)

2024

2023

Viatris collaboration agreement – Amounts receivable from Viatris

$

14,503

$

10,411

Three Months Ended March 31, 

(In thousands)

  

2024

  

2023

YUPELRI net sales (Theravance Biopharma implied 35%)

$

19,329

$

16,434

Summary of the reductions to R&D costs related to reimbursement payments

Three Months Ended March 31, 

(In thousands)

    

2024

    

2023

Viatris

$

189

$

1,753